SCHEMBL30122013

SCHEMBL30122013

CCOC(=O)c1nn(Cc2cc(F)ccc2F)c(Cl)c1CC=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 2/20 0.40
KDM4E B2RXH2 2/20 0.38
PTGER1 P34995 3/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ELANE P08246 3/20 0.37
ROCK2 O75116 1/20 0.37
MDM2 Q00987 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
MAPK1 P28482 2/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23081454 1.00 NPC1 (0.40) NPC1RAB9ALMNATSHRKDM4E
SCHEMBL24709700 0.89 NPC1 (0.35) NPC1RAB9ALMNAKDM4EMEN1
SCHEMBL20477400 0.88 KMT2A (0.45) NPC1RAB9ALMNAKDM4EMEN1
SCHEMBL23081430 0.87 MEN1 (0.43) NPC1RAB9ALMNATSHRPTGER1
SCHEMBL28991077 0.86 NPC1 (0.46) NPC1RAB9ALMNAKDM4EELANE
SCHEMBL25972278 0.86 PTGDR2 (0.38) PTGER1MEN1KMT2AROCK2PTGDR2
SCHEMBL23081377 0.86 TSHR (0.41) NPC1RAB9ALMNATSHRKDM4E
SCHEMBL30122181 0.85 NPC1 (0.40) NPC1RAB9ALMNATSHRKDM4E
SCHEMBL23070332 0.84 NPSR1 (0.38) NPC1RAB9ALMNATSHRKDM4E
SCHEMBL23081536 0.83 P2RX7 (0.38) NPC1RAB9ALMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed
WO-2022258052-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 NPC1 1506/4885RAB9A 1248/4885LMNA 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.